We observed in our study strong overexpression 2+/3+ (2+/3+) of the HER receptors rarely for HER1 (5% of tumours), most frequently for HER2 (26%), HER3 (74%), and for HER4 (51% of the tumours), in general in agreement with other studies (Bieche et al, 2003; Witton et al, 2003; Abd El-Rehim et al, 2004). This evidence concerns the gene ERBB3 and neoplasm.